North America & Europe Varicose Vein Treatment Markets to Post almost a 7% CAGR through 2021, Says M&M in Its New Report Published at MarketPublishers
25 May 2016 • by Natalie Aster
LONDON – Spurred by a wide spectrum of factors, including increasing incidence of varicose vein cases in European and North American regions, ongoing shift towards less-invasive treatment options and procedures, rising healthcare expenditures, improving patient compliance and reliability, and also rising number of aged people, the varicose vein treatment marketplace in Europe and North America is set to rise through 2021 at a CAGR of almost 7%. By 2021, North America’s varicose vein treatment market will likely reach the value of USD 289.7 billion, and Europe’s varicose vein treatment market is anticipated to amount to USD 207.9 million.
Presently, North America commands the bigger share, however, Europe is expected to see the highest growth rates in the five upcoming years owing to favorable government regulative initiatives and expanding adoption of advanced treatment procedures.
In 2015, the market for varicose vein treatment was led by three major companies: Medtronic, AngioDynamics and biolitec AG; together they held a 85% market share.
New research report “Varicose Vein Treatment Market in North America and Europe” prepared by MarketsandMarkets provides an all-encompassing analysis of the market for varicose vein treatment in the North American and European regions. This report offers reliable data on varicose vein treatment products, existing and emerging technologies, key research and development activities, lucrative growth sectors, competitive scenario and major market players. Furthermore, key market growth drivers, restraints, opportunities and challenges are thoroughly discussed in the research study along with a 5-year future outlook.
For other new research reports by M&M follow to this catalogue.